Advancing Atherosclerotic Cardiovascular Disease Trials Through Innovative Imaging Endpoints

As cardiovascular clinical trials evolve, imaging biomarkers have become essential tools for enriching patient populations, evaluating therapeutic response and accelerating study timelines. Among these, the detection of coronary inflammation is emerging as a powerful means of advancing research in atherosclerotic cardiovascular disease (ASCVD).

In this webinar, experts will explore the growing role of imaging endpoints in ASCVD trials, with a focus on the fat attenuation index (FAI) score, a groundbreaking imaging biomarker of coronary inflammation. Attendees will explore how the integration of FAI-based endpoints is set to transform clinical trials in ASCVD.

Attendees will gain an understanding of the scientific basis behind FAI and its validation in large-scale studies. They will learn how this technology enables early disease detection, patient risk stratification and more responsive endpoints. The panel will offer practical guidance on incorporating imaging endpoints into the next generation of ASCVD trials.

The featured speakers will also share insights into best practices in trial planning and execution, including site selection, training and certification, strategies for imaging oversight and data quality assurance.

Register for this webinar today to gain actionable insights on leveraging imaging endpoints to strengthen development strategies in cardiovascular disease trials.

Speakers

Charalambos Antoniades, MD, PhD, FRCP, FESC, Co-Founder and Chief Scientific Officer, Caristo Diagnostics

Dr. Charis Antoniades holds a BHF Chair of Cardiovascular Medicine at the University of Oxford and practices as a Consultant Cardiologist at Oxford University Hospitals. He is the Director, Acute Multidisciplinary Imaging & Interventional Centre, University of Oxford, and the Deputy Head of the Division of Cardiovascular Medicine. He also served as the Chair of the British Atherosclerosis Society from 2021 to 2024 and is involved in several leadership roles within the ESC.

Read more...

His research is focused on the study of the cross-talk between adipose tissue and the cardiovascular system, with a specific interest in the non-invasive imaging of inflammation and the use of artificial intelligence (AI) for risk prediction. He directs the Oxford Heart Vessels and Fat programme, and coordinates large national flagship programmes (such as the UK C19-CRC) and international multicentre studies (e.g., ORFAN study). His research has led to the development of novel AI-derived imaging biomarkers using computed tomography, with a major role in cardiovascular risk prognosis.

He is also deputy editor of Cardiovascular Research and serves on several editorial boards, while he is one of the founders of the Scientists of Tomorrow of the ESC. He has published more than 350 peer-reviewed scientific papers in high-impact journals like The Lancet, Science Translational Medicine, Circulation, JACC, EHJ and others. He is the Founder and Chief Scientific Officer of Caristo Diagnostics, a University of Oxford spinout company.

Read Less...

Message Presenter

Rina Ariga, MBBS, DPhil, MRCP, Medical Director, Medpace

Dr. Rina Ariga is a board-certified cardiologist and physician scientist with over 15 years of academic and commercial clinical research experience. At Medpace, she provides hands-on medical leadership to sponsors and internal study teams engaged in cardiovascular clinical research. She received her Medical degree at Imperial College London with distinction and trained as a junior doctor in London prior to completing her doctorate at the University of Oxford. She was appointed NIHR Academic Clinical Lecturer at Oxford, where she completed cardiology training at the John Radcliffe Hospital and post-doctoral research as the Extraordinary Junior Research Fellow at The Queen’s College, Oxford. She is specialized in multimodality cardiac imaging, heart failure and inherited cardiac conditions, and served as a Consultant Cardiologist in the NHS prior to joining Medpace.

Message Presenter

Andrea Flannery, PhD, Director, Clinical Trial Management, Medpace

Dr. Andrea Flannery is a Director of Clinical Trial Management at Medpace with a PhD specialized in microbiology and device-related infections from the National University of Ireland, Galway. Her therapeutic experience specializes in global cardiovascular clinical trials, including ASCVD, and leads the cardiovascular outcomes trial (CVOT) group within Medpace.

Message Presenter